-
Cetuximab
- indication:For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.
- pharmacologypharmacology:
- mechanism: Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.
- toxicity: Single doses of cetuximab higher than 500 mg/m<sup>2</sup> have not been tested. There is no experience with overdosage in human clinical trials.
- absorprion:
- halflife: 114 hrs
- roouteelimination:
- volumedistribution:
- clearance: